Quest Diagnostics, Inc. (NYSE: DGX) is -9.42% lower on its value in year-to-date trading and has touched a low of $119.59 and a high of $148.62 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The DGX stock was last observed hovering at around $125.66 in the last trading session, with the day’s loss setting it -0.77%.
Currently trading at $124.89, the stock is -1.19% and -5.23% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.59 million and changing -0.61% at the moment leaves the stock -5.77% off its SMA200. DGX registered -9.74% loss for a year compared to 6-month loss of -5.67%. The firm has a 50-day simple moving average (SMA 50) of $2.01 and a 200-day simple moving average (SMA200) of $10.76.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -3.06% gain in the last 1 month and extending the period to 3 months gives it a -7.98%, and is -0.36% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.61% over the week and 2.13% over the month.
Quest Diagnostics, Inc. (DGX) has around 48000 employees, a market worth around $13.83B and $9.25B in sales. Current P/E ratio is 16.68 and Fwd P/E is 13.27. Profit margin for the company is 9.19%. Distance from 52-week low is 4.43% and -15.97% from its 52-week high. The company has generated returns on investments over the last 12 months (7.58%).
Quest Diagnostics, Inc. quarterly earnings per share for the current quarter are estimated at $1.85 with sales reaching $2.28B over the same period.The EPS is expected to grow by 0.41% this year, but quarterly earnings will post 1.60% year-over-year. Quarterly sales are estimated to shrink -2.00% in year-over-year returns.
1,193 institutions hold shares in Quest Diagnostics, Inc. (DGX), with institutional investors hold 92.85% of the company’s shares. The shares outstanding are 111.00M, and float is at 109.72M with Short Float at 2.70%. Institutions hold 92.04% of the Float.
The top institutional shareholder in the company is Vanguard Group Inc with over 13.74 million shares valued at $1.93 billion. The investor’s holdings represent 12.25% of the DGX Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 11.74 million shares valued at $1.65 billion to account for 10.46% of the shares outstanding. The other top investors are State Street Corporation which holds 5.53 million shares representing 4.93% and valued at over $777.55 million, while Victory Capital Management Inc. holds 2.88% of the shares totaling 3.23 million with a market value of $454.52 million.
Quest Diagnostics, Inc. (DGX) Insider Activity
A total of 5 insider transactions have happened at Quest Diagnostics, Inc. (DGX) in the last six months, with sales accounting for 1 and purchases happening 4 times. The most recent transaction is an insider sale by Gregg Vicky B, the company’s Director. SEC filings show that Gregg Vicky B sold 2,500 shares of the company’s common stock on Feb 23 at a price of $126.64 per share for a total of $0.32 million. Following the sale, the insider now owns 16329.0 shares.
Quest Diagnostics, Inc. disclosed in a document filed with the SEC on Feb 22 that Doherty Catherine T. (EVP, Regional Businesses) sold a total of 821 shares of the company’s common stock. The trade occurred on Feb 22 and was made at $126.14 per share for $0.1 million. Following the transaction, the insider now directly holds 70800.0 shares of the DGX stock.
Still, SEC filings show that on Feb 22, PREVOZNIK MICHAEL E (SVP & General Counsel) disposed off 661 shares at an average price of $126.14 for $83379.0. The insider now directly holds 40,206 shares of Quest Diagnostics, Inc. (DGX).
Quest Diagnostics, Inc. (DGX): Who are the competitors?
One of the company’s main competitors (and peers) include UnitedHealth Group Inc. (UNH) that is trading 3.33% up over the past 12 months.IQVIA Holdings Inc. (IQV) lies in the list of competitors of the Quest Diagnostics, Inc. and is 14.52% higher over the same period from DGXCentene Corp. (CNC) is 14.35% up on the 1-year trading charts.
